US Patent Application A1 - Fiber Probiotic Combination for Regulating Cholesterol
Summary
USPTO published patent application US20260108569A1 (A1) on April 23, 2026, for a composition combining at least one fiber and at least one probiotic for oral administration to regulate gut bacteria association with cholesterol levels. The five inventors are Marc Garcia-Gar cera, Sami Damak, Bernard Berger, Fabio Mainardi, and Clara Lucia Garcia-Rodenas. The application was filed on October 30, 2023, under application number 19123666, with CPC classifications spanning A61K compounds including prebiotics and dietary fibers.
“A composition containing a combination of at least one fiber and at least one probiotic can be orally administered to a subject in an amount effective to regulate gut bacteria association with cholesterol levels in the blood of the subject.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published a patent application (A1 publication) for a fiber-probiotic combination composition designed to regulate gut bacteria association with cholesterol levels in subjects. The composition is intended for oral administration in amounts effective to achieve improvements in blood cholesterol levels and prevention or treatment of cardiovascular, circulatory, endocrine system, and nervous system conditions and diseases.\n\nThis patent application, if granted, would give the inventors exclusive rights to this specific combination therapy. Competitors developing similar fiber-probiotic formulations for cholesterol management should monitor this application's prosecution and consider freedom-to-operate analysis. The filing date of October 30, 2023 establishes priority rights for this composition and its stated applications.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS USING A COMBINATION OF AT LEAST ONE FIBER AND AT LEAST ONE PROBIOTIC FOR REGULATING GUT BACTERIA ASSOCIATION WITH CHOLESTEROL
Application US20260108569A1 Kind: A1 Apr 23, 2026
Inventors
Marc GARCIA-GARCERA, Sami DAMAK, Bernard BERGER, Fabio MAINARDI, Clara Lucia GARCIA-RODENAS
Abstract
A composition containing a combination of at least one fiber and at least one probiotic can be orally administered to a subject in an amount effective to regulate gut bacteria association with cholesterol levels in the blood of the subject. The method can achieve at least one result that is improvement of cholesterol levels in the blood, prevention and/or treatment of cardiovascular, circulatory, endocrine system and/or nervous system conditions and/or diseases.
CPC Classifications
A61K 35/747 A61K 31/702 A61K 31/717 A61K 31/732 A61K 31/736 A61K 35/745 A61K 36/55 A61K 36/736 A61P 1/00 A61P 3/06
Filing Date
2023-10-30
Application No.
19123666
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.